Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

endocrine · Mechanism Report

Does the DIO2 rs225014 TT genotype alter type 2 deiodinase function and intracellular T3 signaling?

The TT (Thr/Thr) genotype is the normal wild-type and is not associated with altered D2 function or reduced intracellular T3 signaling; those effects are linked to the Ala92 variant (Thr/Ala or Ala/Ala).

UnsupportedJune 19, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

The DIO2 rs225014 (Thr92Ala) TT genotype is associated with altered type 2 deiodinase function and reduced intracellular T3 signaling in some tissues.

laying out figure…
1 of 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim links the TT genotype to altered deiodinase activity and reduced intracellular T3, but mechanistic and clinical evidence identify TT as the normal reference state. Altered D2 function arises from the Ala92 variant, which mislocalizes the enzyme, triggers ER stress and unfolded protein response, and accelerates proteasomal degradation, resulting in reduced local T4→T3 conversion and tissue-level reductions in T3 signaling. This distinction explains why tissue-specific hypothyroid effects can occur with Ala92 alleles despite normal systemic thyroid tests.

Verified conclusion

The DIO2 rs225014 (Thr92Ala) polymorphism plays a critical role in local thyroid hormone regulation, but clinical and molecular evidence distinguishes between the normal wild-type and its variant states.

Molecular mechanisms of the Thr92Ala polymorphism

  • Wild-type baseline: The TT (Thr/Thr) genotype represents the normal, wild-type reference baseline of the DIO2 gene. It does not exhibit altered enzymatic function, abnormal trafficking, or pathological degradation.
  • Variant pathophysiology: The altered deiodinase function is uniquely driven by the Ala92 variant (Thr/Ala or Ala/Ala genotypes). This genetic variation causes the enzyme to mislocalize and accumulate in the Golgi apparatus rather than remaining in the endoplasmic reticulum.
  • ER stress pathway: This intracellular accumulation triggers endoplasmic reticulum (ER) stress and activates the unfolded protein response. This pathway accelerates ubiquitin-mediated proteasomal degradation, reducing the overall stability and concentration of active type 2 deiodinase (D2) enzymes.

Clinical evidence and tissue-specific signaling

  • Impaired T4-to-T3 conversion: The Thr92Ala variant significantly reduces local, intracellular conversion of thyroxine (T4) to active triiodothyronine (T3). This is especially pronounced in tissues dependent on local T3 production, such as the brain, skeletal muscle, and pituitary gland.
  • Normal serum vs. tissue hypothyroidism: Because systemic thyroid-stimulating hormone (TSH) levels often remain within normal limits, patients carrying the Ala92 variant may experience localized tissue-level hypothyroidism. This is a common mechanism explaining why some hypothyroid patients on levothyroxine (LT4) monotherapy experience persistent cognitive and metabolic symptoms despite normal laboratory panels.

Bottom line

  • The claim that the DIO2 rs225014 TT genotype is associated with altered deiodinase function is unsupported, as TT represents the normal wild-type baseline. Instead, altered deiodinase function, ER stress, and reduced intracellular T3 signaling are specifically caused by the Ala92 variant (Thr/Ala or Ala/Ala).

References

  1. Type 2 Deiodinase A/G (Thr92Ala) Polymorphism Is Associated with ... — academic.oup.com ↗
  2. Pathophysiological relevance of deiodinase polymorphism - PMC — pmc.ncbi.nlm.nih.gov ↗
  3. The type 2 deiodinase Thr92Ala polymorphism and cognitive aging — journals.sagepub.com ↗
  4. The Physiological Functions and Polymorphisms of Type II Deiodinase — pmc.ncbi.nlm.nih.gov ↗
  5. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients — academic.oup.com ↗
  6. Type 2 deiodinase polymorphism causes ER stress and ... - JCI — jci.org ↗
  7. Age Worsens the Cognitive Phenotype in Mice Carrying the Thr92Ala-DIO2 Polymorphism — mdpi.com ↗
  8. Type 2 deiodinase polymorphism causes ER stress and ... — researchexperts.utmb.edu ↗
  9. Endoplasmic Reticulum Stress Decreases Intracellular Thyroid ... — pubmed.ncbi.nlm.nih.gov ↗
  10. DIO2 - an overview | ScienceDirect Topics — sciencedirect.com ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesCan obstructive sleep apnea lower testosterone in men?→Plausible5 sourcesDoes a non-elevated LH with low testosterone suggest secondary hypogonadism?→